OH-PRVEN-OPTCS/CLDGENERA
12.8.2024 14:01:30 CEST | Business Wire | Press release
Proven Optics, a premier IT Financial Management Solution provider, today announced the acquisition of CloudGenera, a provider of innovative cloud financial optimization solutions, furthering its mission to create the industry’s most complete IT financial management application platform. The CloudGenera acquisition is the first of what the company anticipates will be several acquisitions as Proven Optics scales growth and leverages a majority growth investment from Silversmith Capital Partners and strategic investment from ServiceNow.
CloudGenera offers vendor-agnostic IT analytics that equip organizations with the business cases necessary to optimize their technology expenditures. By leveraging advanced AI and machine learning technologies, CloudGenera automates decisions regarding application migration and modernization and significantly improves the accuracy of cloud cost forecasts, thus enhancing IT decision-making processes.
“The acquisition of CloudGenera marks a significant milestone for Proven Optics as we expand our cloud costing product capabilities,” said William Miller, Founding Partner & Co-CEO of Proven Optics. “Together, Proven Optics and CloudGenera will provide a more complete solution that provides our customers with new IT decision analysis capabilities to generate business cases for cloud migration and optimization.”
Proven Optics was founded in 2020 to provide IT and finance leaders with the necessary analytics and insights to make better business decisions by automating the financial management of complex IT budgets. Delivered on the ServiceNow Platform and available in the ServiceNow Store, the Proven Optics Financial Management Application Suite offers additional value for ServiceNow customers looking to add a financial lens to their decision-making.
The acquisition enhances the value that Proven Optics’ customers derive from their investment in ServiceNow as a strategic platform. By offering critical market intelligence, both Proven Optics and CloudGenera customers will benefit from an integrated solution that improves cloud orchestration and decisions related to budgeting and future forecasting, allowing IT finance and cloud teams to manage the entire process within a single workflow and take full advantage of the power of the ServiceNow platform.
“We are excited to join forces with Bill, Ben, and the entire Proven Optics team,” said Brian Kelly, Founder and CEO of CloudGenera who has joined Proven Optics as Executive Vice President of Product. “Together, we will provide customers with a comprehensive set of tools to enhance IT value and facilitate smarter decision-making across their cloud infrastructure.”
About Proven Optics
Proven Optics is a software company that focuses on one thing: Financial Management. Proven Optics helps clients in both IT and finance organizations implement financial management toolsets on the ServiceNow platform, leveraging 20+ years of practitioner experience and 100+ Commercial and Federal implementations. Our solutions enable modernization of financial management functions, providing IT and Finance leaders with the necessary analytics and insights to make better business decisions. For more information or a demonstration of our products, please visit www.provenoptics.com.
About CloudGenera
Founded in 2012, CloudGenera supplies vendor-agnostic IT analytics that arm organizations with the business cases needed to optimize their technology spend. CloudGenera’s proprietary algorithms automate application migration and modernization decisions. For more information visit https://go.cloudgenera.com/.
Proven Optics is helping you move from simplifying and centralizing your IT financials to supercharging your IT financial decision-making and execution.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240812664766/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom